Acitretin in the treatment of severe disorders of keratinization

Blanchet-Bardon, C; Nazzaro, V.; Rognin, C.; Geiger, J M; Puissant, A

doi:10.1016/0190-9622(91)70158-x

Cited by 89 publications

(48 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found five open series, one of which was prospective, describing its use in the ichthyoses. [57][58][59][60] In one, 29 children had conditions including lamellar ichthyosis (9), nonbullous ichthyosiform erythroderma (5), one of whom responded poorly, bullous ichthyosiform erythroderma (4) and Sjögren-Larsson syndrome (3). 57 A patient with Netherton syndrome experienced marked worsening.…”

Section: Congenital Ichthyoses and Keratodermamentioning

confidence: 99%

“…The results in congenital ichthyosiform erythroderma, lamellar ichthyosis and PapillonLefèvre syndrome were judged by the authors empirically as better than those usually reported with etretinate. 59 Milder ichthyoses such as ichthyosis vulgaris and X-linked recessive ichthyosis should not require acitretin therapy. 61 However, six patients with severe X-linked recessive ichthyosis were successfully treated.…”

Section: Congenital Ichthyoses and Keratodermamentioning

confidence: 99%

See 1 more Smart Citation

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology

Ormerod

Campalani

Goodfield

2010

British Journal of Dermatology

126

154

View full text Add to dashboard Cite

Section: Congenital Ichthyoses and Keratodermamentioning

confidence: 99%

Section: Congenital Ichthyoses and Keratodermamentioning

confidence: 99%

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology

Ormerod

Campalani

Goodfield

2010

British Journal of Dermatology

126

154

View full text Add to dashboard Cite

“…Retinoids promote differentiation, and inhibit PMN migration and clonal growth of leukemic cell lines in vitro [6][7][8][9][10]. However, toxicity and in particular teratogenicity have limited their use [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Effects of Systemic Treatment with Liarozole on Cutaneous Inflammation, Epidermal Proliferation and Differentiation in Extensive Plaque Psoriasis

Pelt¹,

Jong²,

Bakker³

et al. 1998

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Liarozole is a novel inhibitor of the enzyme cytochrome P₄₅₀ which has inhibitory effects on the 4-hydroxylation of retinoic acid. Previous studies have shown that liarozole is effective in the treatment of psoriasis. We performed an immunohistochemical study on the lesional skin from 7 patients with extensive plaque psoriasis, who were treated with systemic liarozole 75 mg BID for a period of at least 2 months. The effects of liarozole treatment on clinical and histological parameters were investigated. In particular, the effect of liarozole on the integrin markers CD11b and CD18 was studied.For immunohistochemistry, three consecutive biopsies were taken: before treatment, after 4, and after 8 weeks of treatment. Clinical scores and side effects were recorded before and during treatment.The medication was well tolerated and only mild side effects were reported, which were comparable with hypervitaminosis A. After 2 months of treatment a statistically significant decrease of the extent of body involvement was observed. In the psoriatic plaque, markers for epidermal proliferation and cutaneous inflammation decreased, and markers for epidermal differentiation increased to values comparable to normal skin. The first therapeutic effects in the psoriatic plaque occurred after 4 weeks of treatment, and consisted of a decreased induration, accompanied by a decrease of the total number of inflammatory infiltrate cells and a decreased epidermal ICAM-1 expression. Already after 4 weeks of treatment, a decrease of CD11b-positive cells was observed. Subsequently, after 8 weeks of treatment the recruitment of cycling epidermal cells and the number of involucrin-positive cell layers decreased.The present study demonstrates that liarozole treatment of psoriasis results in a reduction of aspects of cutaneous inflammation and subsequently a reduction of epidermal proliferation and promotion of differentiation. After 4 weeks of treatment, effects are observed on the epidermal ICAM-1 expression and on the CD11b-positive cell population.

show abstract

“…The symptomatic treatment includes topical keratolytic preparations and antiseptics, as well as appropriate systemic antibiotics in order to control cutaneous bacterial and fungal infections. Retinoids are reported to reduce hyperkeratosis in some cases but often seem to be associated with augmented skin fragility and subsequently occurrence of blistering and infections [5,6] . We present the case of a patient suffering from BCIE with a substantial clinical improvement following erythromycin therapy.…”

Section: Introductionmentioning

confidence: 99%

Successful Treatment of Bullous Congenital Ichthyosiform Erythroderma with Erythromycin

Freyhaus¹,

Kaiser²,

Proelss³

et al. 2007

Dermatology

View full text Add to dashboard Cite

Acitretin in the treatment of severe disorders of keratinization

Cited by 89 publications

References 10 publications

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology

Effects of Systemic Treatment with Liarozole on Cutaneous Inflammation, Epidermal Proliferation and Differentiation in Extensive Plaque Psoriasis

Successful Treatment of Bullous Congenital Ichthyosiform Erythroderma with Erythromycin

Contact Info

Product

Resources

About